Your browser doesn't support javascript.
loading
Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials.
Oncology ; 81(2): 135-40, 2011.
Article em En | MEDLINE | ID: mdl-21985828
ABSTRACT

INTRODUCTION:

First-line treatment options utilizing chemotherapy and cytokine-based treatments for patients with metastatic melanoma (MM) are unsatisfactory. We analyzed the clinical outcomes of patients with MM treated in phase I trials of novel agents. We hypothesized that patients included in phase I clinical trials did not have worse outcomes than with the chemotherapy and cytokine-based first-line treatment.

METHODS:

Data of patients with MM treated at The Drug Development Unit between 2004 and 2010 were collected. The response rate (RR) and time to progression (TTP) for first-line therapy were compared to those of phase I trial therapy. Patients acted as their own controls for statistical analyses.

RESULTS:

Sixty-five patients were treated in 31 phase I trials. First-line treatment included dacarbazine or temozolomide in 58 (89%) cases and interferon-α in 5 patients (8%) and cisplatin-based treatment in 2 patients (3%). There was no significant difference in either the RR (11 vs. 14%, p = 0.87) or TTP (90 vs. 53 days, p = 0.15) in patients treated with first-line treatment versus phase I treatment, respectively.

CONCLUSION:

Phase I clinical trials of molecularly targeted agents show clinical activity that is not dissimilar to that of treatment with existing chemotherapy and cytokine-based treatment.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Oncology Ano de publicação: 2011 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Oncology Ano de publicação: 2011 Tipo de documento: Article País de afiliação: Reino Unido